Global Protein Degradation Targeting Chimera (PROTAC) Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Global Protein Degradation Targeting Chimera (PROTAC) Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

As a new type of small molecule drug development technology, PROTAC is receiving more and more attention. Major pharmaceutical companies and biotechnology companies have invested heavily in research and development in the hope of making breakthroughs in this field. With the continuous advancement of technology and the accumulation of clinical data, PROTAC is expected to achieve more breakthroughs in the next few years and provide more possibilities for the development of new drugs.

According to our (Global Info Research) latest study, the global Protein Degradation Targeting Chimera (PROTAC) market size was valued at US$ million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of %during review period.

This report is a detailed and comprehensive analysis for global Protein Degradation Targeting Chimera (PROTAC) market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.

Key Features:

Global Protein Degradation Targeting Chimera (PROTAC) market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2019-2030

Global Protein Degradation Targeting Chimera (PROTAC) market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2019-2030

Global Protein Degradation Targeting Chimera (PROTAC) market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2019-2030

Global Protein Degradation Targeting Chimera (PROTAC) market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2019-2024

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Protein Degradation Targeting Chimera (PROTAC)

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Protein Degradation Targeting Chimera (PROTAC) market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Arvinas, Pfizer, Kymera, Nurix, C4 Therapeutics, Inc., Astellas Pharma Inc., AbbVie, Captor therapeutics, Amgen, Oerth Bio, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation

Protein Degradation Targeting Chimera (PROTAC) market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
Based on CRBN
Based on VHL

Market segment by Application
Breast Cancer
Prostate Cancer
Colorectal Cancer
Pancreatic Cancer
Lymphoma
Androgenic Alopecia
Others

Major players covered
Arvinas
Pfizer
Kymera
Nurix
C4 Therapeutics, Inc.
Astellas Pharma Inc.
AbbVie
Captor therapeutics
Amgen
Oerth Bio
Bayer
Kaituo Pharmaceutical
Haichuang Pharmaceutical
Betta Pharmaceuticals
BeiGene
East China Pharmaceutical Group
Hengrui Medicine

Market segment by region, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Protein Degradation Targeting Chimera (PROTAC) product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Protein Degradation Targeting Chimera (PROTAC), with price, sales quantity, revenue, and global market share of Protein Degradation Targeting Chimera (PROTAC) from 2019 to 2024.

Chapter 3, the Protein Degradation Targeting Chimera (PROTAC) competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Protein Degradation Targeting Chimera (PROTAC) breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2019 to 2030.

Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2019 to 2030.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2019 to 2024.and Protein Degradation Targeting Chimera (PROTAC) market forecast, by regions, by Type, and by Application, with sales and revenue, from 2025 to 2030.

Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of Protein Degradation Targeting Chimera (PROTAC).

Chapter 14 and 15, to describe Protein Degradation Targeting Chimera (PROTAC) sales channel, distributors, customers, research findings and conclusion.